NCT07445581Not yet recruiting
Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients
A Clinical Study on Tanhuo Decoction in the Treatment of Acute Coronary Syndrome Combined With Cerebral Atherosclerosis in the Elderly
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if Tanhuo decoction works to treat acute coronary syndrome combined with cerebral atherosclerosis in the elderly. It will also learn about the safety of Tanhuo decoction. The main questions it aims to answer are: Can Tanhuo decoction reduce inflammatory markers in elderly patients with acute coronary syndrome combined with cerebral atherosclerosis and decrease the occurrence of adverse cardiovascular events? What medical problems do participants have when taking Tanhuo decoction? Researchers will compare Tanhuo decoction to a placebo (a look-alike substance that contains no drug) to see if Tanhuo decoction works to treat acute coronary syndrome combined with cerebral atherosclerosis in the elderly. Participants will:Take Tanhuo decoction or a placebo every day for a week. undergo laboratory tests and echocardiography at baseline (before starting the medication), on day 7, and at 1 month after initiation, and will complete telephone follow-ups during hospitalization and at 1, 3, 6, and 12 months after discharge.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- First submitted
- 1 Jan 2026
- Start date
- 28 Feb 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Jinggang Xia, MD
- Diseases
- Coronary artery disease
- NCT number
- NCT07445581
What you commit to
- Study type: Interventional
- Planned participants: 480
- From 28 Feb 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of bronchial asthma
Other illness
- History of chronic heart failure due to any cause
- History of ischemic stroke, peptic ulcer, active bleeding, or major surgery within the past 3 months
- Contraindication or allergy to aspirin, clopidogrel, ticagrelor, or statins
- History of malignant tumor
- Known allergy to components of traditional Chinese medicine
Lab values
- Hepatic or renal dysfunction, defined as ALT or AST levels \>5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²
- Platelet count \<80×10⁹/L or anemia (hemoglobin ≤100 g/L)
Other
- Patients with persistent hemodynamic instability beyond 24 hours, or those with ACS-related hypotension (SBP \< 90 mmHg or DBP \< 60 mmHg), or requiring coronary artery bypass grafting based on coronary artery lesions
Who the study is looking for
- Hemodynamic stability within 24 hours following treatment for acute coronary syndrome
- A confirmed prior diagnosis of ischemic cerebrovascular disease, or the presence of intracranial or extracranial arterial stenosis ≥50%, as verified by carotid and cerebrovascular ultrasound after admission
- Manifestations consistent with fire-heat syndrome, including tongue body appearance, tongue coating, stool characteristics, mental state, facial complexion, breathing pattern, presence of fever, pulse features, oral sensation, and urine properties. A total score of ≥7 points based on the weighted scoring system for each item indicates the presence of fire-heat syndrome.
- Age ≥ 60 years old
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital of Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.